新天药业(002873) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 200,346,913, a decrease of 8.58% year-over-year, and year-to-date revenue was CNY 558,633,030.72, down 15.47% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2025 was CNY 10,414,861.82, a decline of 66.03%, while year-to-date net profit was CNY 16,180,940.17, down 73.47% year-over-year[5] - Basic and diluted earnings per share for Q3 2025 were CNY 0.0427, representing a decrease of 67.97% compared to the same period last year[5] - Total operating revenue for the current period was ¥558,633,030.72, a decrease of 15.5% from ¥660,845,257.81 in the previous period[18] - Net profit for the current period was ¥16,180,940.17, down 73.5% from ¥60,999,761.23 in the previous period[19] - Basic earnings per share decreased to ¥0.0663 from ¥0.2645, a decline of 75%[19] Cash Flow - Cash flow from operating activities for the year-to-date period increased by 112.07% to CNY 115,995,922.34[5] - The company's cash flow from operating activities showed a significant decline, impacting overall liquidity[19] - Operating cash flow for the current period was ¥115,995,922.34, a significant increase from ¥54,698,235.80 in the previous period, representing a growth of approximately 112%[20] - Total cash inflow from operating activities was ¥664,864,099.45, compared to ¥630,523,324.47 in the previous period, indicating a year-over-year increase of about 5.4%[20] - Cash outflow from operating activities decreased to ¥548,868,177.11 from ¥575,825,088.67, reflecting a reduction of approximately 4.7%[20] - The company’s cash flow from operating activities showed a strong performance, contributing positively to the overall cash position despite challenges in investment activities[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,092,933,355.39, an increase of 7.30% from the end of the previous year[5] - Total liabilities rose to ¥829,619,387.83, compared to ¥755,785,472.79, marking an increase of 9.7%[17] - The equity attributable to shareholders of the parent company increased to ¥1,263,313,967.56 from ¥1,194,715,847.70, a growth of 5.7%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period was 31,075[11] - The largest shareholder, Shanghai Xintian Zhi Pharmaceutical Biotechnology Co., Ltd., holds 30.92% of shares, amounting to 75,485,566 shares, with 48,796,844 shares pledged[11] Investments and Capital - The company plans to increase its registered capital from ¥231,491,231.00 to ¥244,103,806.00[12] - The company held 8,806,030 shares in its repurchase account, accounting for 3.61% of total shares[12] Operational Metrics - Significant changes in financial metrics included a 43.38% increase in cash and cash equivalents due to improved cash flow from operations[9] - Short-term borrowings decreased by 80.73% to CNY 306,242,291.69, primarily due to repayment of bank loans[9] - Research and development expenses for the current period were ¥32,148,963.09, an increase of 7.4% from ¥29,913,962.65[18] Other Financial Metrics - Non-operating income for Q3 2025 totaled CNY 439,808.75, down from CNY 2,626,392.42 year-to-date[7] - Deferred income tax liabilities increased to ¥33,817,862.08 from ¥22,105,205.11, reflecting a growth of 53%[18] - Total operating costs decreased to ¥545,335,763.62 from ¥609,497,817.29, reflecting a reduction of 10.5%[18] - The company's total assets increased to ¥2,092,933,355.39, up from ¥1,950,501,320.49, representing a growth of 7.3%[17] - Cash inflow from financing activities was ¥431,900,000.00, down from ¥509,000,000.00, showing a decline of about 15.1%[21] - Net cash flow from financing activities improved to ¥3,356,325.89 from a negative cash flow of ¥11,301,145.05 in the previous period[21]